Mesoblast (MESO) Return on Capital Employed (2017 - 2023)
Mesoblast (MESO) posted quarterly Return on Capital Employed of 2.49% for Q2 2023, up 690.0% year-on-year from 0.32% in Q2 2022, and up 48.22% on a QoQ basis from 4.81% in Q1 2023.
Mesoblast (MESO) Return on Capital Employed (2017 - 2023) Analysis & Trends
Mesoblast (MESO) has reported Return on Capital Employed for 7 consecutive years, with 2.49% the latest figure, recorded in Q2 2023.
- Quarterly Return on Capital Employed rose 690.0% year-over-year to 2.49% in Q2 2023, while the trailing twelve-month figure through Jun 2023 was 2.49% (up 690.0% YoY) and the FY2025 annual result came in at 9.94%, down 7.0% from the prior year.
- Return on Capital Employed grew to 2.49% in Q2 2023 per MESO's latest filing, from 4.81% in the prior quarter.
- Over the last five years, Return on Capital Employed for MESO reached as high as 2.49% in Q2 2023 and fell as low as 16.81% in Q2 2019.
- A 5-year average of 11.07% and a median of 11.77% in 2021 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2019 — Return on Capital Employed tumbled 656 bps — and 2022, when it soared 908 bps.
- Year by year, Return on Capital Employed stood at 13.18% in 2019, then increased by 16 bps to 11.13% in 2020, then slumped by 31 bps to 14.64% in 2021, then jumped by 62 bps to 5.56% in 2022, then jumped by 55 bps to 2.49% in 2023.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 2.49%, 4.81%, and 5.56% for Q2 2023, Q1 2023, and Q4 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Mesoblast | 2.08 Bn | 1.95 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | -2.49% |
| Mar 31, 2023 | -4.81% |
| Dec 31, 2022 | -5.56% |
| Sep 30, 2022 | -8.34% |
| Jun 30, 2022 | -9.39% |
| Mar 31, 2022 | -12.74% |
| Dec 31, 2021 | -14.64% |
| Sep 30, 2021 | -13.45% |
| Jun 30, 2021 | -13.45% |
| Mar 31, 2021 | -12.25% |
| Dec 31, 2020 | -11.13% |
| Sep 30, 2020 | -10.93% |
| Jun 30, 2020 | -8.52% |
| Mar 31, 2020 | -11.29% |
| Dec 31, 2019 | -13.18% |
| Sep 30, 2019 | -14.61% |
| Jun 30, 2019 | -16.81% |
| Mar 31, 2019 | -15.70% |
| Dec 31, 2018 | -15.44% |
| Sep 30, 2018 | -12.18% |